BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: We find that BCL2 expression levels predict sensitivity to ABT-199 in CML and NCB progenitors, and that high NCB BCL2 levels may explain the reported hematologic toxicities in ABT-199-treated patients.